Neogen Chemicals (542665) Aug 2026 Filing Analysis

Commence commercial production at the rebuilt Dahej replacement plant. — target: Commercial production commencement (+4 more commitments)

Optimize the base business by shifting toward larger-volume, more capital-efficient molecules and reducing product complexity. — target: Develop/scale individual molecules of approximately INR 50 crore-INR 100 crore revenue

Ramp battery-chemical sales as US customers shift to non-China/non-FEOC suppliers. — target: Majority of FY27 battery-business revenue in H2, with customer shift expected from January 2027 (+1 more commitment)

Expand capabilities in adjacent high-end complex chemistries. (+1 more commitment)

Receive Morita's equity contribution to the battery-material joint venture. — target: USD 20 million equity contribution (+4 more commitments)

Battery-chemical scale increased from the previously described Pakhajan plan toward a combined salt capacity of about 5.5 KTA initially, comprising roughly 3 KTA at the greenfield facility and 4 KTA at Dahej for LiPF6-related salt capacity as described by management. Neogen also identified further expansion options: 2 KTA could be added in 9-12 months and another 5 KTA in 15-18 months. The business is therefore moving from planned capacity toward a scalable platform, though commissioning is delayed. (5 expanding)

No updated export percentage was disclosed. International battery demand and customer approvals, however, are progressing: several international customers have approved electrolyte-salt samples, three to four large consumers are actively discussing supply, and customers are moving toward non-FEOC suppliers during 2026 ahead of the 2027 requirement. The export opportunity is therefore expanding in strategic importance, although current revenue share cannot be quantified. (5 expanding)

Regulatory positioning strengthened and became more commercially actionable. Previously, Neogen was positioned as a beneficiary of non-China and non-FEOC requirements. In the latest quarter, management reported provisional approvals from multiple global customers, expected audits by Q1 FY27, and strong interest driven by US 45X non-FEOC requirements and Chinese price volatility. This converts a regulatory theme into an emerging order and qualification pipeline. (1 expanding)

The customer-qualification moat strengthened. Previously extracted evidence referred to provisional approval from four international customers and audits by four electrolyte manufacturers. In Q2 FY26, Neogen reported that one leading Indian gigafactory had completed PPAP approval for commercial electrolyte supply, while salt had provisional approval pending final improvements. Salt volume agreements covering 5.5 KTA were already in place. This increases commercial qualification and contracted-volume visibility, although final salt approval remains pending. (5 expanding)

The technology moat expanded through the formation of the Indo-Japan Neogen-Morita joint venture. Neogen will hold at least 80% of the JV, which will produce LiPF6 salt using established Japanese technology. Separately, MUIS/Mitsubishi technology supports electrolyte production. Management says the combination improves quality, approval prospects, productivity and operating cost, while creating a non-FEOC supply option. (4 expanding, 1 shifted)

The earlier Rs. 300 crore FY26 battery revenue expectation has been materially reduced to Rs. 30-40 crore because Indian battery plants and customer approvals were delayed. However, FY27 guidance has shifted to Rs. 400-500 crore, indicating a strong expected acceleration once customers transition suppliers and domestic gigafactories ramp up. (5 accelerating across 5 signals, 3 leading indicators)

Battery chemicals are moving from an early-stage business into a large future growth engine. Current FY26 revenue is guided at only Rs. 30-40 crore, but management expects Rs. 400-500 crore in FY27 and Rs. 2,400-2,900 crore at full utilisation by FY29. The opportunity is therefore accelerating, although the near-term ramp has been delayed. (5 accelerating across 5 signals, 1 leading indicator)

Reported revenue growth strengthened in the latest quarter: Q4 FY26 revenue was Rs. 247 crore, up 22% year on year, compared with FY26 revenue growth of 11%. The inorganic chemicals segment grew 145% year on year in Q4, while organic chemicals grew 7%. Growth was primarily volume-led, making the latest quarter an acceleration in consolidated revenue momentum. (3 accelerating, 2 new trend across 5 signals)

The core business has been upgraded to Rs. 950-1,050 crore revenue in FY27, with a possible Rs. 1,100-1,200 crore in FY28 even without major new capacity. Growth should come from Dahej ramp-up, better product selection and larger-volume molecules. — Base business revenue guidance: FY27 guidance raised from Rs. 875-950 crore; FY28 expected growth of 10-15%

Export markets remain an important expansion route, with sales spread across the USA, Europe, Middle East, China, Korea and Japan. Exports accounted for 30% of Q1 FY27 sales, and international customer engagement is increasing for battery salts.

The balance-sheet risk has intensified in absolute terms. Consolidated debt reached INR 1,078 crore and net debt INR 900 crore after the INR 200 crore NCD issue; management expects peak debt of INR 1,800 crore around FY28. Although trailing DSCR was 2.1x and near-term term-loan repayments are only INR 40-50 crore, cash flows depend partly on delayed insurance receipts and future battery utilization. (5 intensifying, 2 high-severity)

The risk has worsened materially. Management acknowledged a 6-12 month delay in Indian cell commissioning and reduced FY26 battery-chemical revenue guidance from the earlier INR 300 crore expectation to only INR 30-40 crore. Electrolyte demand is now expected to strengthen from Q4 FY26 or later, depending on Ola and Exide ramp-up. (4 intensifying, 1 easing, 3 high-severity)

The regulatory opportunity remains important but timing risk has become more visible. Customers are expected to shift at different times during calendar 2026, with some waiting until Q3-Q4, while the company now expects the strongest demand in H2 FY27. Full compliance also requires the entire critical-mineral supply chain to be non-FEOC, which could narrow the immediately addressable market. (2 intensifying, 2 easing, 1 stable, 4 high-severity)

The risk is currently visible through margin pressure, although the presentation does not isolate lithium-price effects. Standalone expenditure grew 10% versus 7% revenue growth, and EBITDA margin fell from 18.9% to 16.9%. Consolidated EBITDA margin fell from 17.8% to 14.4%. Management also describes pricing as volatile and lithium prices as a factor in the FY29 revenue range. (5 intensifying, 2 high-severity)

The risk intensified sharply. Consolidated operating cash flow was negative INR 231.48 crore in FY26 versus positive INR 195.98 crore in FY25. Inventories rose to INR 568.23 crore from INR 309.13 crore and trade receivables rose to INR 380.36 crore from INR 200.22 crore. The current ratio fell to 1.17 from 1.36, while supplier-finance liabilities were INR 234.71 crore. (1 intensifying, 2 easing, 2 stable, 5 high-severity)